Recently, non-opioid medications have made significant progress. Early in 2025, the FDA approved suzetrigine under the commercial name Journavx. It relieves pain following surgery by specifically inhibiting pain impulses in the nerves. Suzetrigine lowers the risk of addiction, in contrast to opioid medicines. This has the potential to change the game, lower the number of opioid-related deaths, and improve healthcare.
How do you think this will affect pain management in the future?
MBH/PS
Opioid fear has always been prevalent among medical professionals due to its possible effect of addiction. This drug could be a game changer by providing pain relief and other effects of opioids while providing fewer side effects.
This could shift pain care toward safer, non-addictive options, especially after surgery.
If widely adopted, it may reduce opioid dependence while still controlling pain effectively.
Suzetrigine , the recently FDA approved non-opioid medicine holds promise when it comes to reducing moderate to severe acute pain without the potential for addiction.
Very true, opioids have a high risk of dependency, which in case of suzetrigine will be eliminated. This can also be a game changer for safer management.
Exactly. Suzetrigine adoption could eliminate the opioid use in post-surgical cases, at the same time keeping the pain under control. This can lead to safer care option without the addiction trap.
Agreed. It effectively helps in relieving acute pain by selectively targeting NaV1.8 channels.